B.S., 1973, Chemistry, Rensselaer Polytechnic Institute, NY
Ph.D., 1979, Biochemistry, Cornell University, NY
Postdoctoral research: Massachusetts Institute of Technology and Harvard University
For my first sixteen years on the faculty at UW I used Drosophila genetics to study a highly conserved proto-oncogene, Abl and a TGF-beta superfamily member growth factor, Dpp. In 2000, I transitioned my research from classical genetics to the new, at that time, chemical genetic approaches. Over the past fifteen years my research activities, funding and publications have focused on chemical biology and drug discovery. During that time I have also had leadership roles in the Department of Oncology, the Carbone Cancer Center Experimental Therapeutics Program and the Small Molecule Screening & Synthesis Facility at UW. In addition I have participated regularly in NIH review panels focused on high throughput screening, drug discovery and core facilities. My research interests are focused on academic drug discovery through research in my own laboratory as well as collaborative efforts with several other UW-Madison laboratories. Projects in my laboratory funded by NIH, JDRF and MDA focused on chemical biology investigations of TGF-beta signal transduction, specifically on Smad protein-protein interactions, including a JDRF grant. We identified small peptide inhibitors of several Smad protein interactions that perturbed the signaling pathway in cells. We also published an extensive mutational analysis of the Smad3 amino acids mediating specific protein-protein interactions. The application of these studies to intimal hyperplasia is currently the subject of a funded R01 to Dr. Craig Kent on which I am a co-investigator. I am currently involved in collaborative high throughput screening projects on therapy induced senescence, epigenetic pathways, cell proliferation in intimal hyperplasia and remodeling, and the discovery of novel natural products with antibiotic and antifungal activity.
2017Ericksen SS, Wu H, Zhang H, Michael LA, Newton MA, Hoffmann FM, Wildman SA. Machine Learning Consensus Scoring Improves Performance Across Targets in Structure-Based Virtual Screening. J Chem Inf Model. 2017 Jun 27. doi: 10.1021/acs.jcim.7b00153. [Epub ahead of print] PubMed PMID: 28654262. Voter AF, Killoran MP, Ananiev GE, Wildman SA, Hoffmann FM, Keck JL. A High-Throughput Screening Strategy to Identify Inhibitors of SSB Protein-Protein Interactions in an Academic Screening Facility. SLAS Discov. 2017 May 1:2472555217712001. doi: 10.1177/2472555217712001. [Epub ahead of print] PubMed PMID: 28570838.
Djamali A, Wilson NA, Sadowski EA, Zha W, Niles D, Hafez O, Dorn JR, Mehner TR, Grimm PC, Hoffmann FM, Zhong W, Fain SB, Reese SR. Nox2 and Cyclosporine-Induced Renal Hypoxia. Transplantation. 2016 Jun;100(6):1198-210. doi: 10.1097/TP.0000000000001137. PubMed PMID: 26950727; PubMed Central PMCID: PMC4874919.
Zhao Z, Wang L, James T, Jung Y, Kim I, Tan R, Hoffmann FM, Xu W. Reciprocal Regulation of ERα and ERβ Stability and Activity by Diptoindonesin G. Chem Biol. 2015 Dec 17;22(12):1608-21. doi: 10.1016/j.chembiol.2015.10.011. Epub 2015 Dec 3. PubMed PMID: 26670079; PubMed Central PMCID: PMC4767166.
Bansal, M., Yang, J., Karan, C., Menden, M. P., Costello, J. C., Tang, H., Xiao, G., Li, Y., Allen, J., Zhong, R., Chen, B., Kim, M., Wang, T., Heiser, L. M., Realubit, R., Mattioli, M., Alvarez, M. J., Shen, Y., NCI-DREAM Community (including Hoffmann, F. M.), Gallahan, D., Singer, D., Saez-Rodriguez, J., Xie, Y., Stolovitzky, G., and Califano, A. A Community Computational Challenge to Predict the Activity of Pairs of Compounds. Nat. Biotechnol., 32(12): 1213-1222, 2014.
Goel, S. A., Guo, L.-W., Wang, B., Guo, S., Roenneburg, D., Ananiev, G. E., Hoffmann, F. M., and Kent, K. C. High-Throughput Screening Identifies Idarubicin as a Preferential Inhibitor of Smooth Muscle versus Endothelial Cell Proliferation. PLoS One, 9(2):e89349, 2014.
Goodman, C. A., McNally, R. M., Hoffmann, F. M., and Hornberger, T. A. Smad3 Induces Atrogin-1, Inhibits mTOR and Protein Synthesis, and Promotes Muscle Atrophy in Vivo. Mol. Endocrinol., 27(11): 1946-1957, 2013.
Ozawa, M., Shimojima, M., Goto, H., Watanabe, S., Hatta, Y., Kiso, M., Furuta, Y., Horimoto, T., Peters, N. R., Hoffmann, F. M., and Kawaoka, Y. A Cell-Based Screening System for Influenza A Viral RNA Transcription/Replication Inhibitors. Sci. Rep., 3:1106, 2013.
Zeng, H., Wu, J., Bedford, M. T., Sbardella, G., Hoffmann, F. M., Bi, K., and Xu, W. A TR-FRET-Based Functional Assay for Screening Activators of CARM1. ChemBioChem, 14(7): 827-835, 2013.
Das, S., Becker, B. N., Hoffmann, F. M., and Mertz, J. E. Reversal of Transforming Growth Factor-β Induced Epithelial-to-Mesenchymal Transition and the ZEB Proteins. Fibrogenesis Tissue Repair, 5(Suppl 1): S28, 2012.
Tomasini-Johansson, B. R., Johnson, I. A., Hoffmann, F. M., and Mosher, D. F. Quantitative Microtiter Fibronectin Fibrillogenesis Assay: Use in High Throughput Screening for Identification of Inhibitor Compounds. Matrix Biol., 31: 360-367, 2012.